Schizophrenia is a complex disease involving the dysregulation of numerous brain circuits and patients exhibit positive symptoms (hallucinations, delusions), negative symptoms (anhedonia), and cognitive impairments. We have shown that the antipsychotic efficacy of positive allosteric modulators (PAMs) of both the M muscarinic receptor and metabotropic glutamate receptor 1 (mGlu) involve the retrograde activation of the presynaptic cannabinoid type-2 (CB) receptor, indicating that CB activation or potentiation could result in a novel therapeutic strategy for schizophrenia. We used two complementary assays, receptor-mediated phosphoinositide hydrolysis and GIRK channel activation, to characterize a CB PAM scaffold, represented by the compound EC21a, to explore its potential as a starting point to optimize therapeutics for schizophrenia. These studies revealed that EC21a acts as an allosteric inverse agonist at CB in both assays and exhibits a mixed allosteric agonist/negative allosteric modulator profile at CB depending upon the assay used for profiling. A series of compounds related to EC21a also functioned as CB inverse agonists. Overall, these results suggest that EC21a exhibits complicated and potentially assay-dependent pharmacology, which may impact interpretation of studies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11636628 | PMC |
| http://dx.doi.org/10.1080/10799893.2024.2431986 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ganaxolone: A Review in Epileptic Seizures Associated with Cyclin-Dependent Kinase-Like 5 Deficiency Disorder.
Paediatr Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Oral ganaxolone (ZTALMY), a synthetic analogue of the endogenous neuroactive steroid allopregnanolone, acts as a positive allosteric modulator of synaptic and extra-synaptic γ-aminobutyric acid (GABA) type A receptor function in the CNS. In the EU and the UK, it is approved for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients aged 2-17 years. In a multinational phase III study (Marigold), 17 weeks' therapy with adjunctive ganaxolone, administered orally three times daily with food, significantly reduced 28-day major motor seizure frequency from baseline versus placebo in patients aged 2-19 years with CDD-associated refractory epilepsy.
View Article and Find Full Text PDFNon‐clinical evidence for modulating synaptic CSF biomarkers by E2511, a novel small molecule TrkA biased positive allosteric modulator.
Alzheimers Dement
December 2024
Eisai Ltd, Hatfield, United Kingdom
Background: Cholinergic innervation is particularly vulnerable in many neurodegenerative diseases such as Alzheimer’s diseases. Nerve growth factor (NGF) plays a major role in the maintenance and function of cholinergic neurons, and a decrease in trophic signalling by NGF‐Tropomyosin receptor kinase A (TrkA) contributes to cholinergic and synaptic degeneration. E2511 is a novel small molecule TrkA biased positive allosteric modulator showing an increase in specific trophic signalling via direct binding to TrkA with a potential to recover and reinnervate damaged cholinergic neurons.
View Article and Find Full Text PDFA Therapeutic Small Molecule Enhances γ‐Oscillations and Improves Cognition/Memory in Alzheimer’s Disease Model Mice.
Alzheimers Dement
December 2024
The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Background: Brain rhythms provide the timing for recruitment of brain activity required for linking together neuronal ensembles engaged in specific tasks. The γ‐oscillations (30‐120 Hz) orchestrate neuronal circuits underlying cognitive processes and working memory. High temporal resolution recording methods, such as magnetoencephalography, have made it clear that Alzheimer’s disease (AD) patients, starting as early as the mild cognitive impairment (MCI) stage, have diminished γ‐oscillations even before the Aβ load takes full effect.
View Article and Find Full Text PDFRestoring Cognitive functions: Unveiling the Procognitive and Neurotrophic Impact of Chronic Administration of a Selective A5‐GABAA Receptor Positive Allosteric Modulator in Mouse Models of Amyloid Load and Tau Phosphorylation.
Alzheimers Dement
December 2024
Centre for Addiction and Mental Health, Toronto, ON, Canada
Background: Dysregulated GABA/somatostatin (SST) signaling has been implicated in psychiatric and neurodegenerative disorders. The inhibition of excitatory neurons by SST+ interneurons, particularly through α5‐containing GABAA receptors (α5‐GABAAR), plays a crucial role in mitigating cognitive functions. Previous research demonstrated that an α5‐positive allosteric modulator (α5‐PAM) mitigates working memory deficits and reverses neuronal atrophy in aged mice.
View Article and Find Full Text PDFEfficacy of a Muscarinic (M1) Positive Allosteric Modulator, SUVN‐I7016031 in Animal Models of Dementia.
Alzheimers Dement
December 2024
Suven Life Sciences, Hyderabad, Telangana, India
Background: SUVN‐I7016031 is a novel and selective positive allosteric modulator (PAM) of the M1 subtype of the muscarinic acetylcholine receptors (mAChRs). The proposed primary indication for SUVN‐I7016031 is in the treatment of dementia such as Alzheimer’s disease dementia (ADD) and Parkinson’s disease dementia (PDD). In the current research, the pharmacological properties of SUVN‐I7016031 in various types of dementia were investigated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!